Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKL15508
- Development stage
- Phase 2
- Lead developer
- SK Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SKL15508 is a small molecule partial agonist of the alpha7 nicotinic acetylcholine receptor (α7 nAChR), developed by SK Biopharmaceuticals for the treatment of cognitive impairment associated with schizophrenia (CIAS). The drug is designed to address cognitive deficits in schizophrenia that are not adequately managed by current antipsychotic therapies. Preclinical studies have shown that it potently relieves signs of cognitive impairment in animal models and demonstrates synergistic effects when combined with existing antipsychotics. It is being developed as an oral formulation and has also been considered for other cognition disorders[1][3][5].
02
Targets
CHRNA7 (α7 nicotinic receptor)
Beyond the preview
Go deeper on SKL15508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKL15508.